Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Twelves

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.
Clinical Pharmacology and Therapeutics|December 17, 2008
A dynamic model of hand-and-foot syndrome in patients receiving capecitabineE Hénin, B You, E VanCutsem, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patientsJ Cassidy, C Twelves, D Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancerF Efficace, L Biganzoli, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancerH J Mackay, M Hill, C Twelves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development GroupP Schöffski, S Riggert, P Fumoleau, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2007
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancerA R Clamp, P Schöffski, J W Valle, et al.
British Journal of Cancer|November 21, 1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusionL Paz-Ares, R Kunka, D DeMaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.
Clinical Pharmacology and Therapeutics|December 17, 2008
A dynamic model of hand-and-foot syndrome in patients receiving capecitabineE Hénin, B You, E VanCutsem, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patientsJ Cassidy, C Twelves, D Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.
European Journal of Cancer (Oxford, England : 1990)|April 20, 2004
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancerF Efficace, L Biganzoli, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancerH J Mackay, M Hill, C Twelves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development GroupP Schöffski, S Riggert, P Fumoleau, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2007
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancerA R Clamp, P Schöffski, J W Valle, et al.
British Journal of Cancer|November 21, 1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusionL Paz-Ares, R Kunka, D DeMaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusionJ P Stevenson, D DeMaria, J Sludden, et al.
Pageof 8